The Anti-Diabetic PPARγ Agonist Pioglitazone Inhibits Cell Proliferation and Induces Metabolic Reprogramming in Prostate Cancer

The authors suggested that Pioglitazone reduces prostate cancer (PCa) cell proliferation and induces metabolic and epithelial changes, highlighting the potential of repurposing metabolic drugs for PCa therapy.